Peter Chambré

Appointed 2016. Peter Chambré is Chair of Cancer Research Technology Ltd, the commercialisation arm of Cancer Research UK and Immatics N.V., a company developing new cancer immunotherapy treatments. He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006. Peter is a Director of Our Future Health.